nach oben

Erschienen in:

08.01.2021 | Review

Metabolic Effects of Endoscopic Duodenal Mucosal Resurfacing: a Systematic Review and Meta-analysis

verfasst von: Guilherme Henrique Peixoto de Oliveira, Diogo Turiani Hourneaux de Moura, Mateus Pereira Funari, Thomas R. McCarty, Igor Braga Ribeiro, Wanderley Marques Bernardo, Vitor Massaro Takamatsu Sagae, João Remi Freitas Jr, Gabriel Mayo de Vieira Souza, Eduardo Guimarães Hourneaux de Moura

Erschienen in: Obesity Surgery | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Duodenal mucosal resurfacing (DMR) is an innovative endoscopic bariatric and metabolic therapy (EBMT) emerging in recent years. It uses the duodenum to achieve better glycemic and weight control. This study aimed to evaluate in a critical and systematic way the metabolic effects of this procedure. Electronic searches were performed evaluating the DMR procedure based on predefined inclusion and exclusion criteria. Changes in measured outcomes were evaluated using random-effects models by computing weighted mean differences (MD) and corresponding 95% CIs between pre-and post-procedure metabolic characteristics. Four studies were selected for qualitative and quantitative analysis. DMR demonstrated beneficial glycemic and hepatic metabolic effects among patients with non-insulin dependent type 2 diabetes (T2D) at 3 and 6 months post-procedure.

Nur mit Berechtigung zugänglich

World Health Organization. Obesity and Overweigh. 2020 [cited 2020 Sep 12]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

World Health Organization. Diabetes. 2020 [cited 2020 Dec 9]. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes.

Kotinda APST, de Moura DTH, Ribeiro IB, et al. Efficacy of intragastric balloons for weight loss in overweight and obese adults: a systematic review and meta-analysis of randomized controlled trials. Obes Surg. 2020;30:2743–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32300945CrossRef

de Miranda Neto AA, de Moura DTH, Ribeiro IB, et al. Efficacy and safety of endoscopic sleeve gastroplasty at mid term in the management of overweight and obese patients: a systematic review and meta-analysis. Obes Surg. 2020;30:1971–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32107706CrossRef

Eckel RH, Kahn SE, Ferrannini E, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab. 2011;96:1654–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21602457CrossRef

Hartemink N, Boshuizen HC, Nagelkerke NJD, et al. Combining risk estimates from observational studies with different exposure cutpoints: a meta-analysis on body mass index and diabetes type 2. Am J Epidemiol. 2006;163:1042–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16611666CrossRef

Schienkiewitz A, Schulze MB, Hoffmann K, et al. Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)–Potsdam Study1–3. Am J Clin Nutr. 2006;84:427–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16895894CrossRef

Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32278004CrossRef

Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15111519CrossRef

10.

Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Trans Meet Am Surg Assoc. 2003;121:160–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14530719

11.

Aldoheyan T, Hassanain M, Al-Mulhim A, et al. The effects of bariatric surgeries on nonalcoholic fatty liver disease. Surg Endosc. 2017;31:1142–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27405478CrossRef

12.

de Moura EGH, Ribeiro IB, Frazão MSV, et al. EUS-guided Intragastric injection of botulinum toxin a in the preoperative treatment of super-obese patients: a randomized clinical trial. Obes Surg. 2019;29:32–9. Available from: http://link.springer.com/10.1007/s11695-018-3470-yCrossRef

13.

Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17060767CrossRef

14.

McCarty TR, Thompson CC. Bariatric and metabolic therapies targeting the small intestine. Tech Innov Gastrointest Endosc. 2020;22:145–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32905221CrossRef

15.

van Baar ACG, Nieuwdorp M, Holleman F, et al. The duodenum harbors a broad untapped therapeutic potential. Gastroenterology. 2018;154:773–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29428335CrossRef

16.

Mudaliar S, Henry RR. The incretin hormones: from scientific discovery to practical therapeutics. Diabetologia. 2012;55:1865–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22555471

17.

Verdam FJ, Greve JWM, Roosta S, et al. Small intestinal alterations in severely obese hyperglycemic subjects. J Clin Endocrinol Metab. 2011;96:E379–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21084402CrossRef

18.

Cherrington AD, Rajagopalan H, Maggs D, et al. Hydrothermal duodenal mucosal resurfacing. Gastrointest Endosc Clin N Am. 2017;27:299–311. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28292408CrossRef

19.

Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRef

20.

Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;

21.

Jadad AR, Moore RAA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/721797CrossRef

22.

GRADE Working Group. GRADEpro guideline development tool [software]. McMaster Univ. 2015.

23.

Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ [Internet]. 2003;327:557–60. Available from: http://www.bmj.com/cgi/doi/10.1136/bmj.327.7414.557CrossRef

24.

Magee C, Everson M, Mok J, et al. PTH-040 Endoscopic duodenal mucosal resurfacing in type 2 diabetes – a single centre experience. Endoscopy. BMJ Publishing Group Ltd and British Society of Gastroenterology; 2018. p. A32.2-A32. Available from: http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2018-BSGAbstracts.61

25.

van Baar ACG, Beuers U, Wong K, et al. Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results. JHEP Reports. 2019;1:429–37. Available from:http://www.ncbi.nlm.nih.gov/pubmed/32039394CrossRef

26.

van Baar ACG, Nieuwdorp M, Holleman F, et al. Single duodenal mucosal resurfacing elicits improvements in glycaemic and hepatic parameters in type 2 diabetes mellitus: Complete 1 year results from the first prospective multicenter study. United Eur Gastroenterol J. 2018;A135–747. Available from: http://journals.sagepub.com/doi/10.1177/2050640618792819

27.

Neto MG, Rajagopalan H, Becerra P, et al. 829 Endoscopic duodenal mucosal resurfacing improves glycemic and hepatic parameters in patients with type 2 diabetes: data from a first-in-human study. Gastroenterology. 2016;150:S174. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0016508516306722CrossRef

28.

van Baar AC, Nieuwdorp M, Batterham R, et al. Improvement in hepatic transaminases over 12 months after single procedure duodenal mucosal resurfacing in type 2 diabetes patients. United Eur Gastroenterol J. 2017;A161–836. Available from: http://journals.sagepub.com/doi/10.1177/2050640617725676

29.

van Baar A, Smeele P, Vriend TM, et al. Sa1962 duodenal mucosal resurfacing (DMR) combined with GLP-1 receptor agonism may eliminate insulin treatment while maintaining glycaemic control and improving overall metabolic health in type 2 diabetes. Gastrointest Endosc. 2019;89:AB260. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0016510719304845CrossRef

30.

Mraz M, Marcovitch I, Lankova I, et al. 1131-P: endoscopic duodenal submucosal laser ablation for the treatment of type 2 diabetes mellitus: results of first-in-human pilot study. Diabetes. 2019;68:1131-P. Available from: http://diabetes.diabetesjournals.org/lookup/doi/10.2337/db19-1131-P

31.

Rajagopalan H, Cherrington AD, Thompson CC, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016;39:2254–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27519448CrossRef

32.

Aithal G, Sakai N, Chouhan M, et al. PS-112-endoscopic duodenal mucosal resurfacing improves hepatic fat fraction, glycemic and lipid profiles in type 2 diabetes. J Hepatol. 2019;70:e70–1. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0618827819301240CrossRef

33.

van Baar ACG, Holleman F, Crenier L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut. 2020;69:295–303. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31331994CrossRef

34.

Mingrone G, Hopkins D, Aithal G, et al. 121-LB: durable glycemic improvements after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (T2D): 48-week results from the REVITA-2 European cohort. Diabetes. 2020;121–LB. Available from: http://diabetes.diabetesjournals.org/lookup/doi/10.2337/db20-121-LB

35.

Sherifali D, Nerenberg K, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33:1859–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20484130CrossRef

36.

Buhmann H, le Roux CW, Bueter M. The gut–brain axis in obesity. Best Pract Res Clin Gastroenterol. 2014;28:559–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25194175

37.

van Olst N, Meiring S, de Brauw M, et al. Small intestinal physiology relevant to bariatric and metabolic endoscopic therapies: Incretins, bile acid signaling, and gut microbiome. Tech Innov Gastrointest Endosc [Internet]. 2020;22:109–19. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2590030720300878CrossRef

38.

Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes, Obes Metab. 2018;20:5–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29364588

39.

Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29154965

40.

Starekova J, Reeder SB. Liver fat quantification: where do we stand? Abdom Radiol. 2020;45:3386–99. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33025153

41.

Caussy C, Reeder SB, Sirlin CB, et al. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018;68:763–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29356032CrossRef

42.

Safety & effectiveness of duodenal mucosal resurfacing (DMR) using the Revita™ system in treatment of type 2 Diabetes. [cited 2020 Dec 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT03653091

43.

Evaluation of the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita™ System in Subjects With Type 2 Diabetes on Insulin Therapy (REVITA-T2Di). [cited 2020 Dec 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT04419779

44.

Effect of DMR in the Treatment of NASH (DMR_NASH_001). [cited 2020 Dec 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT03536650

45.

de Moura EGH, Ponte-Neto AM, Tsakmaki A, et al. Histologic assessment of the intestinal wall following duodenal mucosal resurfacing (DMR): a new procedure for the treatment of insulin-resistant metabolic disease. Endosc Int Open. 2019;7:E685–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31098390CrossRef

46.

Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology. 2012;142:1100-1101.e2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22326433

47.

Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013;36:1859–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23801799CrossRef

48.

Davies NK, O’Sullivan JM, Plank LD, et al. Altered gut microbiome after bariatric surgery and its association with metabolic benefits: a systematic review. Surg Obes Relat Dis. 2019;15:656–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30824335CrossRef

Titel: Metabolic Effects of Endoscopic Duodenal Mucosal Resurfacing: a Systematic Review and Meta-analysis
verfasst von: Guilherme Henrique Peixoto de Oliveira
Diogo Turiani Hourneaux de Moura
Mateus Pereira Funari
Thomas R. McCarty
Igor Braga Ribeiro
Wanderley Marques Bernardo
Vitor Massaro Takamatsu Sagae
João Remi Freitas Jr
Gabriel Mayo de Vieira Souza
Eduardo Guimarães Hourneaux de Moura
Publikationsdatum: 08.01.2021
Verlag: Springer US
Erschienen in: Obesity Surgery / Ausgabe 3/2021
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-020-05170-3

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Laparoscopic Greater Curvature Plication for the Treatment of Obesity: a Systematic Review

Returning to Surgery—Experience, Discussions and Consensus

Long-Term Outcome of Proximal Versus Very-Very Long Limb Roux-en-Y Gastric Bypass: the Roux-Limb to Common Channel Ratio Determines the Long-Term Weight Loss

Weight Loss as the First-Line Therapy in Patients with Severe Obesity and Obstructive Sleep Apnea Syndrome: the Role of Laparoscopic Sleeve Gastrectomy

LSG vs MGB-OAGB: 5-Year Follow-up Data and Comparative Outcome of the Two Procedures over Long Term—Results of a Randomised Control Trial

Bariatric Surgery Is Protective Against Renal Function Decline in Severely Obese Patients in the Long-Term

Update Chirurgie